Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer
Lenvatinib plus pembrolizumab was not associated with improved survival when compared with re-challenge PT in patients with a platinum-free interval of over 6 months. Re-challenge PT remains a valid option for PT-treated, recurrent, or advanced ECs, especially in patients with a substantially long platinum-free interval.
Authors
- Chin-Ku Liu
- Jem-Kun Chen (ORCID: https://orcid.org/0000-0003-3670-6710)
- Lou Sun (ORCID: https://orcid.org/0000-0001-5561-7110)
- Yu‐Hsiang Shih (ORCID: https://orcid.org/0000-0003-2731-1215)
- Hsin‐Hua Chen (ORCID: https://orcid.org/0000-0002-7304-4587)
- Sheau-Feng Hwang
- Shao-Jing Wang (ORCID: https://orcid.org/0000-0001-7654-2699)
- Chien‐Hsing Lu (ORCID: https://orcid.org/0000-0001-7860-4320)
- Ting-Fang Lu (ORCID: https://orcid.org/0009-0000-1338-5614)
- Yen‐Fu Chen (ORCID: https://orcid.org/0000-0002-9446-2761)
- Shih-Tien Hsu
Institutions
- Ling Tung University (TW)
- National Taiwan University of Science and Technology (TW)
- National Chung Hsing University (TW)
- Tunghai University (TW)
- Providence University (TW)
- China Medical University (TW)
- Taichung Veterans General Hospital (TW)
- Chung Shan Medical University (TW)
- National Yang Ming Chiao Tung University (TW)
Publication Details
- Journal
- BMC Medicine
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1186/s12916-025-03989-0
- Citations
- 3
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.17
Funders
- Taichung Veterans General Hospital